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Aim: A high versatile microfluidic platform is proposed to design, in a one-step 
strategy, PEGylated crosslinked hyaluronic acid nanoparticles (cHANPs) entrapping 
a magnetic resonance imaging contrast agent and a dye for multimodal imaging 
applications. Materials & methods: Clinically relevant biomaterials were shaped in the 
form of spherical NPs through a microfluidic flow focusing approach. A comparison 
between post processing and simultaneous PEGylation is reported to evaluate the 
potentiality of the chemical decoration of the cHANPs in microfluidics. Results: An 
accurate control of the NPs in terms of size, PEGylation and loading was obtained. 
Furthermore, in vitro cell viability is reported and their ability to boost the magnetic 
resonance imaging signal is also confirmed. Conclusion: The proposed microfluidic 
approach reveals its ability to overcome several limitations of the traditional processes 
and to become an easy-to-use platform for theranostic applications.
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online: 17 August 2017
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Traditional approaches for generating 
nanoparticles (NPs) by the solvent displace-
ment route, are conventionally performed by 
bulk polymer nanoprecipitation process, in 
other words, by mixing the two phases in a 
batch vessel. Even though these technolo-
gies present numerous advantages such as the 
possibility to treat high volumes, they also 
suffer from serious drawbacks, such as poor 
flexibility of the formulation process and 
control of the NPs size, low tunability of the 
process in real-time [1,2]. In the nanomedi-
cine field, special attention should be paid 
to the precise control of the physicochemical 
properties of the formulated NPs to achieve 
an optimal biodistribution. Furthermore, 
significant aspects comprise surface func-
tionalization, like coating with polyethylene 
glycol (PEG) or targeting agents, high pay-
load capability and controlled drug release. 
For all these aspects, the nanoprecipitation 
process must be reproducible and robust. 
Under these requirements, new possibilities 
to control NP formation by the nanoprecipi-
tation route have emerged from microfluidic 
solutions [3,4].
Microfluidic approaches permit synthe-
sizing micro and nanostructures having a 
narrow size distribution and further enable 
to easily guarantee high encapsulation effi-
ciency and stable crosslinking reaction [5–7]. 
Among the several benefits that microdimen-
sion of microfluidic devices provides [8,9], 
there is also the ability to use products librar-
ies of different materials rapidly by chang-
ing composition and flow rates. Indeed, the 
production of particles having a coefficient 
of variation (defined as the ratio between 
size’ standard deviation and mean *100) is 
less than 5% and high encapsulation effi-
ciency is efficiently achieved; furthermore, 
parallelization on microfluidic chips allows 
high throughput and multiple analysis and 
reaction at a time [10].
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In this perspective, Karnik et al. [11] synthesized 
biodegradable PLGA–PEG polymeric NPs through 
a hydrodynamic flow focusing by nanoprecipitation 
where particle size and drug loading can be varied by 
flow rates, polymer composition and concentration. 
Later [12,13], a similar flow focusing microfluidic device, 
controlling the nanoprecipitation, showed that the co-
encapsulation of hydrophilic and hydrophobic antican-
cer drugs with high encapsulation efficiency, platinum 
prodrug and docetaxel, respectively. Very recent studies 
on such technology reported potential in vivo applica-
tions with hybrid/PLGA NPs designed as therapeutic 
and imaging agents [14]. In another detailed microflu-
idic study, Capretto et al. [15] presented the formation 
of block copolymer stabilized NPs (hybrid NPs), by 
examining the effects of operational fluidic conditions 
and the feed concentration of polymers and actives on 
the size characteristics and the polymer coverage of the 
organic actives. Pluronic F127 was used as a model 
block copolymer while highly hydrophobic β-carotene 
was used as a model drug. Results demonstrated the 
existence of competitive reactions leading to the forma-
tion of two types of NPs, in other words, either with or 
without loading β-carotene in the core–shell structure. 
Other microfluidic-based nanoprecipitation processes 
are reported using another biocompatible and biode-
gradable polymer that is chitosan, but this time playing 
on the aqueous solubility of the polymer as a function 
of the pH. Chitosan presents a pKa around 6.2 at room 
temperature and thus, once solubilized at low pH, the 
mixing with a basic solution through microfluidic 
channels may induce the polymer nanoprecipitation. 
This idea was reported in recent articles [16,17], using 
hydrophobically modified chitosan, that is, by graft-
ing palmitic acid on primary amines of chitosan with 
activation of acid by N-hydroxysuccinimide esters. The 
produced NPs were ranging in size between 50 and 
300 nm and served to precisely encapsulate and release 
active hydrophobic principle (paclitaxel) over 1 week.
Nanoprecipitation processes in such devices open 
new benefits and new advantages regarding size con-
trol, drug encapsulation control and improvement 
[18–20].
In our recent work [21], we explored novel microflu-
idic strategies rationally designed to synthesize cross-
linked hyaluronic acid nanoparticles (cHANPs) down 
to 50 nm to be applied in magnetic resonance imag-
ing (MRI). A tight control of the nanoprecipitation 
behavior, of the crosslinking reaction and of the encap-
sulation efficiency of the MRI contrast agents (CAs), 
 Gd-DTPA is reached.
MRI was selected because it is a routinely applied 
diagnostic modality, due to its noninvasivity and 
ability to obtain 3D tomographical information of 
soft tissues. Furthermore, it can be used for visual-
izing functions of cardiac, brain and central nervous 
system, as well as detecting tumor [22]. However, this 
technique suffers from the lack of sensitivity and infor-
mation obtained from a simple unenhanced magnetic 
resonance image and, consequently, more than 35% 
of all clinical MRI scans utilize CAs to improve these 
aspects by selectively relaxing the water molecules near 
the complex [23].
Gadolinium-based CAs are the most used in the 
clinical MRI with over 10 million contrast enhanced 
MRI scans every year, because of their relatively high 
stability and inertness in the body even if they still 
lack in tissue specificity and exhibit low relaxivity [23]. 
Moreover, they could cause adverse effects, such as 
nephrotoxicity [24] and also the risk of intracranial 
deposition has been recently reported [25] earning the 
attention of the US FDA.
In these perspectives, several strategies have been 
investigated to overcome limitations of the clinical 
relevant CAs using nanotechnology [26–33]. How-
ever, the use of the microfluidic approaches to design 
nanostructures able to tune the relaxometric proper-
ties of the clinically approved CAs for MRI was still 
 missing [21].
Herein, starting from the evidence of the previous 
work [21,34], the same microfluidic platform is enforced 
to entrap several diagnostic agents within the cHANPs 
simultaneously for multimodal imaging applications. 
Furthermore, a new combination of biomaterials, thio-
lated hyaluronic acid (HA-SH) and mPEG-vinylsul-
fone (PEG-VS), is also presented by optimizing the 
same microfluidic approach, proving the versatility of 
the proposed microfluidic platform by applying our 
strategies to different materials. In this last case, the 
simultaneous reaction of the HA-SH and PEG-VS to 
produce in a one-step strategy the PEGylated cHANPs 
encapsulating directly one or more active compounds 
is therefore carried on and size, shape and in vitro relax-
ivity analysis are also reported. Finally, a comparison 
between the traditional PEGylation of the cHANPs 
and the PEGylated cHANPs produced by the one-step 
strategy is reported.
Materials & methods
Materials
Sodium hyaluronate (M
w
 = 42 kDa) was purchased 
from Bohus Biotech (Strömstad, Sweden). Hyaluro-
nate thiol (HA-SH), (M
w
 = 50 kDa) and mPEG-
vinylsulfone (PEG-VS), (M
w
: 2kDa), was purchased 
from Creative PEGWorks. Diethylenetriaminepen-
taacetic acid gadolinium(III) dihydrogen salt hydrate 
Gd-DTPA (M
w
 = 547.57 g/mol); Acetone (CHRO-
MASOLV, for HPLC, ≥99.8%; molecular formula 
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Figure 1. Microfluidic device.A schematic representation of the ‘Droplet Junction Chip: 190 μm’ with two 
configurations T- and X- junction, which can be used in combination.
Non-solvent
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CH
3
COCH
3
; M
w
 = 58.08); ethanol (ACS reagent, 
≥99.5% (200 proof), absolute; molecular formula 
CH
3
CH
2
OH; M
w
 = 46.07); divinyl sulfone (or vinyl 
sulfone) (DVS) contains <650 p.p.m. hydroquinone 
as inhibitor; purity 97%; density 1.117 g/ml at 25°C 
(lit.); molecular formula C
4
H
6
O
2
S; M
w
 = 118.15 mp); 
Sodium hydroxide NaOH (ACS reagent, ≥97.0%, 
M
w
 = 40.00); ATTO633 652 g/mol were purchased 
by Sigma-Aldrich Co (MO, USA). PEG–fluorescein 
isothiocyanate (FITC) (M
w
 = 1 kDa) is purchased 
from Nanocs Inc. (NY, USA); HRP-conjugated strep-
tavidin, 1-Ethyl-3-(3 dimethylaminopropyl)-carbodi-
imide and N-hydroxysuccinimide and streptavidin (1 
mg/ml) were purchased from Sigma-Aldrich Co. Cy7- 
PEG1KDa-NH
2
 and Fitc- PEG1KDa-NH
2
 were pur-
chased from Nanocs Inc. The WST-1 assay was pur-
chased from Sigma-Aldrich Co. The water, used for 
synthesis and characterization was purified by distilla-
tion, deionization and reserve osmosis (Milli-Q Plus; 
Merck, Darmstadt, Germany).
Microfluidic set-up for flow focusing approach
A quartz microfluidic device ‘Droplet - Junction Chip’ 
(depth × width 190 μm × 390 μm), purchased from 
Dolomite Centre Ltd, was used. The device has a flow 
focusing geometry with a 90° angle between the inlets 
to enhance the diffusion process [21]. On the chip, there 
are two separate droplet junctions, which can be used 
in combination. For all experiments, we have used only 
X-junction with three inlet channels and a single out-
let channel that can be used to mix and react three 
reagents. A schematic representation was presented in 
Figure 1.
Preparation of cHANPs
Different flow rates were tested and the influence of 
the flow rate ratio, defined as the ratio of volume flow 
rate solvent and volume flow rate nonsolvent, was 
determined. For the feasibility study, an aqueous solu-
tion containing HA concentrations ranging from 0.01 
to 0.1% wt/v was tested. The initial solution was kept 
under continuous stirring for at least 4 h and then 
injected through the middle channel. The flow rate 
of the middle channel was kept constant unvaried at 
30 μl/min. Acetone, used as nonsolvent and injected 
through the side channels, was laterally injected to 
induce nanoprecipitation by a flow focusing approach. 
A total of 4% v/v DVS, used as a crosslinker for HA, 
was mixed with acetone before injecting within the 
microfluidic device. The flow rates of the side channels 
were constantly at 110 μl/min. Precipitated NPs were 
collected in a Petri glass containing about 25 ml of 
nonsolvent and kept under continuous stirring. Each 
experiment was repeated at least ten-times.
Simultaneous encapsulation of Gd-DTPA & 
fluorophores
Several concentrations of fluorophores at least 
1 nmol/100 μl, ATTO633 and ATTO488, were mixed 
with HA aqueous solution together with  Gd-DTPA at 
0.1% wt/v.
Loading capability and encapsulation efficiency 
were calculated by Induced Coupled Plasma (ICP-MS) 
- NexION 350. NPs were suspended in a solution of 
deionized water at a concentration of 150,000 parti-
cles/ml. All data were collected and processed using 
the Syngistix Nano Application Module. Gd was mea-
sured at m/z 157 using a 100 μs dwell time with no 
settling time.
Stability & swelling behavior of cHANPs
ICP-MS was used to assess one-half of the solution 
for the total concentration of Gd3+ ions loaded within 
the NPs. The other half of the solution was filtered 
using 0.45 μm filter and the filtrate was analyzed for 
Gd3+ ions. The concentration of loaded fluorophore 
was determined using spectrofluorimeter (λ
ex/em
 488–
550 nm).
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In vitro cytotoxicity of cHANPs
An adenocarcinomic human alveolar basal epithelial 
cells (A549) was used. The cells were cultured in Dul-
becco’s modified Eagle’s medium containing 10% fetal 
bovine serum and L-glutamine (2.9 mg/ml) at 37°C in 
water-saturated air supplemented with 5% CO
2
. For 
the cytotoxicity measurements, the cells were plated in 
96-well plates for 24 h before the addition of the NPs. 
Fresh medium containing an increasing concentra-
tion of NPs was added to each well and the cells were 
incubated for 24 h. At the end of the incubation time, 
the cytotoxicity of the NPs was tested using an WST-1 
assay (Sigma-Aldrich, MI, USA). Briefly, phosphate-
buffered saline (PBS) containing WST-1 was added to 
each well and the cells were incubated for 30 min, 1, 2, 
4, 12 and 24 h. Spectral absorption of the samples was 
measured at 450 nm with ELISA Reader (Biotek, VT, 
USA). The number of live cells is proportional to the 
amount of formazan produced.
Quantification of carboxyl groups on the 
surface of cHANPs
Back titration method was performed to directly quan-
tify carboxylic groups on the surface of cHANPs. In 
brief, 10 ml of cHANPs (0.1 mg/ml) was dispersed in 
20 ml of 0.01 M NaOH solution, stirred for 30 min 
and then pH annotated. A standard solution of 
0.01 mM HCl, was used as the titrant. After each addi-
tion of titrant the solution was stirred magnetically for 
1 min and the pH was recorded. From the difference of 
NaOH and HCl concentration at equivalent point, the 
molar concentration of carboxylic sites was calculated. 
The titration was repeated on a second NP sample to 
check for reproducibility.
Conjugation with PEG-NH2-Dye
The formation of an amide bond between the COOH 
groups on the NP surface and the NH
2
 end groups 
of the PEG labeled with fluorophore was adopted as 
a strategy of attack to carry out the reaction of direct 
PEGylation. Especially for each reaction, PEG1KDa 
amino and labeled with different fluorophores (Cy7-
PEG1KDa-NH
2
 and FITC-PEG1KDa-NH
2
) were 
used. The activation of the carboxylated surface of 
the cHANPs occurred after contact for 10 min with 
500 μl of the starting sample to a solution of 1-Ethyl-
3-(3 dimethylaminopropyl)-carbodiimide (230 μl 
at 70 mM) and N-hydroxysuccinimide (230 μl at 
21 mM). Thereafter, 2mM of NH
2
-PEG1KDa-Dye 
was added, allowing to react in the dark for 4 h and 
in a slight rotation. The excess reagents were removed 
by ultracentrifugation (30,000 r.p.m., 15°C, 10 min) 
or spin-x corning system (4000 r.p.m., 20°C, 10 min) 
and the pellet was suspended in a phosphate buffer (pH 
6.8). The amount of reagents was stabilized basing on 
the quantification, carried out by titration of the car-
boxyl groups available on the surface of the cHANPs.
Quantification of PEG concentration
The amount of PEG conjugated to cHANPs was deter-
mined by spectrofluorimetric (ENSPIRE Multimode 
Plate Reader PerkinElmer). All measurements were 
performed in triplicate. The calibration line was set in 
the range of 0–80 nmol/ml (Ex/Em 480–550).
Synthesis of PEGylated crosslinked 
nanoparticles by nanoprecipitation in 
microfluidics in a one-step manner
For the feasibility study, an aqueous solution contain-
ing thiolated HA (HA-SH) concentrations ranging 
from 0.01 to 0.1% wt/v was tested. The initial solution 
was kept under continuous stirring for at least 4 h and 
then mixed with PEG-vinylsulfone (PEG-VS) (rang-
ing from 0.4 to 1% v/v) at neutral pH and at 4°C to 
avoid the crosslinking reaction before nanoprecipita-
tion occurs within the microfluidic device. Then, 
HA-SH and PEG-VS solution was injected through 
the middle channel. The flow rate of the middle chan-
nel was kept constant at 30 μl/min. Acetone, used as 
non-solvent and injected through the side channels, 
was laterally injected to induce nanoprecipitation by a 
flow focusing approach. The flow rates of the side chan-
nels were unchanged at 110 μl/min. Precipitated NPs 
were collected in a Petri glass containing about 25 ml 
of nonsolvent and kept under continuous stirring. In 
the literature studies, hydrogels between HA-SH and 
PEG-VS were obtained through a Michael addition in 
PBS at 37°C. The molar ratio of thiol groups to vinyl-
sulfone groups was kept at 1.2 [35,36]. In our microflu-
idic platform, a study on the reagents was conducted to 
create, at the nozzle section, the nucleophilic addition 
of a carbanion (HA-SH) to unsaturated carbonyl com-
pound (PEG-VS). Several experiments were carried 
out to promote the reaction and to reduce suddenly 
growth’s step after the nucleation phase. Each success-
ful experiment was repeated at least ten-times.
Purification and characterization of 
nanoparticles
A Spectra Por Cellulose Membrane 6 (Molecular 
Weight Cut Off MWCO 50,000) was used for puri-
fication protocol. A typical procedure consists of load-
ing collected samples into dialysis tube and keeping the 
buffer solution under continuous stirring at 130 r.p.m. 
The concentration gradient of water was slowly added 
to the buffer solution to avoid aggregation and diffusion 
phenomena across the membrane. Dynamic light scat-
tering was used to determine NP size. NPs were con-
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centrated by ultracentrifugation or by rotavapor R-300. 
The recovery was performed at 15°C, at 60000 r.p.m. 
for 10 min. After these treatments, a 100 μl of puri-
fied samples were deposited on a polycarbonate Isopore 
Membrane Filter (0.05 and 0.1 μm) by ultrafiltration 
vacuum system. The precipitated or deposited particles 
were gold palladium coated, and a ULTRA PLUS field 
emission scanning electron microscope (FE-SEM Carl 
Zeiss, Oberkochen, Germany) was used to observe par-
ticles’ morphology. Transmission electron microscope 
(TEM), stimulated emission depletion (STED) were 
also used to characterize the samples.
In vitro MRI of Gd- loaded PEGylated cHANPs
Empty NPs and Gd-DTPA loaded NPs were tested by 
in vitro MRI and results were compared with Magnev-
ist and Gd-DTPA in water as a control. After vigorous 
stirring, changes in relaxation time (T
1
) were evalu-
ated at 1.5 Tesla by Minispec Bench Top Relaxometer 
(Bruker Corporation) by adding 300 μl of the sample 
in a glass tube [37]. The relaxation time distribution 
was obtained by CONTIN Algorithm. The relaxation 
spectrum was normalized on the CONTIN processing 
parameters. The integral of a peak corresponds there-
fore to the contribution of the species exhibiting this 
peculiar relaxation to the relaxation time spectrum [38]. 
Experiments were repeated at least five times.
Fourier transform infrared spectroscopy
Fourier transform infrared spectra (FT-IR) were 
collected from Nicolett 6700 FT-IR spectrometer 
(Thermo Scientific). All the IR spectra of the speci-
men were collected at 0.09 cm-1 resolution with 2 min 
interval. Thiolated HA, mPEG-Vinylsulfone and 
PEGylated cHANPs were analyzed to confirm if the 
reaction has taken place. Spectra were recorded and 
analyzed for signal assignation.
Results
Simultaneous encapsulation of different 
agents within the cHANPs
A schematic representation of the microfluidic device is 
reported in Figure 1. The same X-junction chip is used 
to perform all the experiments.
To produce cHANPS for multimodal imaging 
applications, an HA solution containing a model 
dye (ATTO633 or ATTO488), at 1 nmol/100 ml, 
and Gd-DTPA at 0.1% wt/v is added to the middle 
channel. No influence on the nanoprecipitation and 
crosslinking reaction is observed and, consequently, 
the flow focusing behavior is kept at standard condi-
tion (HA 0.05% wt/v and solvent flow rate 30 μl/min 
– nonsolvent flow rate 110 μl/min), as defined in our 
previous work [21].
FE-SEM characterization confirms the NP’ size of 
about 40 nm even after several days in water (Figure 2A) 
while STED image of cHANPs (Figure 2B) loaded with 
ATTO633 and Gd-DTPA shows the encapsulation of 
the fluorophore.
Batch PEGylation reaction of cHANPs
To reduce potentially adhesive interactions of colloids 
with intracellular components in vivo, the surface of 
cHANPs has been coated with PEG. In the design of 
NPs for both drug-delivery and imaging applications, 
the addition of PEG to NPs represents a crucial step to 
reduce reticuloendothelial system uptake and increases 
circulation time versus uncoated counterparts. Indeed, 
the PEGylation has several advantages: a prolonged 
residence in the body, a decreased degradation by 
metabolic enzymes and a reduction or elimination of 
protein immunogenicity.
Using back titration, the concentration of carboxylic 
groups is determined by making them to react with an 
excess volume of base solution at a known concentra-
tion and then titrating the resulting mixture with the 
standardized acid solution. To optimize PEGylation 
reaction, we first perform quantitative characterization 
of carboxyl functionalities of cHANPs. Using back titra-
tion, we can quantify the number of surface functional-
ities, providing important information about the surface 
physicochemical properties and the effects on the quality 
and reproducibility of the functional nanomaterial. We 
estimate about 15 nmol of carboxylic group/mg of NPs.
As expected, PEGylation produces a chemical deco-
ration of the particles inducing a larger NP size distri-
butions due to the PEG-corona. Indeed, the measured 
size of the cHANPs decorated with PEG-FITC (1 
KDa) is of about 60 nm diameter. However, it rep-
resents a significant result to prove the stability of the 
cHANPs undergone to chemical decoration and the 
possibility to maintain the dimension of the cHANPs 
under 100 nm preserving potentially a uniform in vivo 
biodistribution. Previously ζ-potential results demon-
strated that cHANPs have a negatively charged surfaces 
(-40 mV), attributed to the presence of deprotonated 
carboxyl groups of HA. In details, PEGylation reduces 
the carboxylic groups from 15 ± 2.5 to 7 ± 1.5 nmol/ml, 
proving that some COOH– groups have not reacted or 
not directly exposed on the NP surface for PEGylation. 
However, as expected, the ζ-potential of the NPs was 
slightly decreased by PEGylation (-15 mV), due to the 
reduction of the carboxylic acids of HA. PEGylation 
is also useful to assess the surface stability of the NPs 
during the chemical decoration and the ability to retain 
the loaded Gd compound during the bioconjugation. 
This result places cHANPs as a good candidate for the 
delivery of active compounds on a specific target.
2216 Nanomedicine (Lond.) (2017) 12(18)
Figure 2. Simultaneous encapsulation of different agents within the crosslinked hyaluronic acid nanoparticles. 
(A) FE-SEM and (B) STED images of cHANPs loaded contemporary with ATTO633 and Gd-DTPA after 48 h in water. 
Batch PEGylation reaction. (C) FE-SEM (D) TEM (E) STED images of loaded cHANPs after conjugation reaction with 
PEG1000-FITC at standard process conditions after 48 h in water. 
cHANP: Crosslinked hyaluronic acid nanoparticle; FE-SEM: Field emission scanning electron microscope; 
STED: Stimulated emission depletion; TEM: Transmission electron microscope.
200 nm 200 nm
100 nm 100 nm 300 nm
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SEM, TEM and STED images of cHANPs after 
PEGylation reaction are reported in Figure 2C, D & E. 
cHANPs subjected to direct PEGylation have main-
tained their spherical structure despite the presence of 
a higher surface roughness and a slight increment in 
size due to the chemical decorations.
In vitro cytotoxicity of nanoparticles
Typically, structural alterations of NPs in aqueous 
solutions, in cell-culture medium, might also affect 
and change the final results of the in vitro toxicologi-
cal studies. Therefore, cytotoxicity tests are essential 
to assess preliminarily the biocompatibility of the 
cHANPs after the process. Understanding the behav-
ior of NPs at the time of toxicological assay may play 
a crucial role in the interpretation of its results. The 
mechanical stability and the enzymatic degradation of 
the NPs are determined by the degree of crosslinking 
of HA structures. As highlighted by studies of Lai, HA 
sheets incorporated different concentrations of DVS in 
a range between 0 and 50 mM had a good cytocompat-
ibility2. For this study, the toxicity of loaded cHANPs 
is tested using a WST-1 assay, which is based on the 
conversion of a water-soluble tetrazolium salt (yellow-
ish in color) to water insoluble formazan (purple color) 
by living cells. Scalar concentrations of cHANPs are 
tested in a range between 10 and 100 μg/ml. It is evi-
dent that the cHANPs showed no detectable cytotoxic-
ity in vitro (Figure 3).
The varied NP–cellular localization and interaction 
might lead to various modes of toxicity. Even NPs of the 
same material can show completely different intracel-
lular behavior due to, for example, slight differences in 
surface coating, charge and size. It has been reported 
that especially the NP size determines the efficiency of 
cellular uptake and subsequent intracellular processing.
The disruption of the NPs inside the cell greatly 
influences the resulting toxic effects. The cytotoxic-
ity could be attributed to the chemical composition of 
the nanostructure, but it should be considered that the 
NPs destabilization results in the release of their con-
tent into intracellular compartments, which can pres-
ent synergic cytotoxic effects. This cytotoxicity can be 
desired, in antitumor treatments, or undesired during 
NPs application for diagnostics purposes. Further-
more, an excellent cell uptake of the NPs guarantees 
the efficient cell MRI and intracellular drug delivery. 
Preliminary cytotoxicity results on cHANPs are prom-
ising to improve the application of the nanomedicine 
in the diagnostic field.
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Figure 3. In vitro cytotoxicity. A549 cell viability 
expressed as a percentage of the value obtained with 
a concentration of cHANPs in a range between 10 and 
100 μg/ml for three different time intervals. The error 
bars represent the standard deviations calculated from 
three independent experiments. 
cHANP: Crosslinked hyaluronic acid nanoparticle.
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Synthesis of PEGylated crosslinked nanoparticles 
by nanoprecipitation in microfluidics in a one-
step manner
While in the above reported paragraph the PEGylation 
has been performed and optimized after the synthe-
sis and the purification of Gd-loaded NPs. In this 
session, we intend to demonstrate the versatility of 
our designed microfluidic platform by synthesizing 
PEGylated cHANPs (PEG-cHANPs) in microfluidics 
through a co-nanoprecipitation process of HA-SH and 
PEG-VS at the same condition just used to produce 
cHANPs but avoiding the batch pegylation reaction 
of our NPs.
In this perspective, we have also obtained HA-PEG 
hydrogels NPs (of about 70 nm) using as aqueous solu-
tion 0.05% wt/v thiolated HA (HA-SH) and 0.8% 
v/v PEG-vinylsulfone (PEG-VS). This further study 
enables the exploitation of PEG coating and the effects 
of the nanoprecipitation on the flow-focusing behavior 
exclusively due to the presence of another polymer with 
non-negligible molecular weight (PEG-VS = 2 KDa). 
As expected, lower concentrations of PEG-VS lead 
to the formation of swelling particles while higher 
concentrations provoke uncontrolled precipitation of 
PEG-VS and flow instability.
In our microfluidic device, at the nozzle section, an 
effective nucleophilic addition of a carbanion (HA-
SH) to unsaturated carbonyl compound (PEG-VS) 
should be achieved (Figure 4A).
TEM and FE-SEM images of the collected morphol-
ogies are showed in Figure 4B & C, respectively. We can 
observe that collected NPs maintain their shape even 
after 48 h in water due to a strong crosslinking reaction 
performed together with nanoprecipitation, encapsula-
tion of Gd-DTPA and PEGylation of cHANPs. TEM 
image Figure 4B shows a different electron density 
between the core and the shell, that can give a previous 
indication of the presence of an outer covering coating 
different from the cHANPs before the PEGylation.
Fourier transform infrared spectra
FT-IR analysis is performed to confirm the effective-
ness of the reaction. Comparative FTIR spectra of 
HA-SH, PEG-VS and PEGylated cHANPs are showed 
in Figure 5. The analysis shows that the PEGylated 
cHANPs do not exhibit the double bond C = C, 
observed for PEG-VS at 750 cm-1, due to the Michael 
addition reaction between the double bond of the PEG-
VS and thiol group of HA. Furthermore, the success of 
the reaction is also guaranteed by the presence of the 
peak at 600 cm-1 that indicates the C-S bond stretch-
ing. Nevertheless, results on PEGylated cHANPs also 
present the peak at 1245 cm-1 associated with C-SH 
vibration [39] related to the residual not reacted thiols of 
the precursor HA-SH. Further details are reported in 
Supporting Information.
FT-IR analysis finally reports that microfluidic 
platform to produce PEGylated cHANPs can accu-
rately control the tuning of the crosslinking reaction 
to improve relaxometric properties and stability of the 
system.
In vitro MRI of Gd-loaded PEGylated cHANPs
In vitro relaxivity is studied for loaded and unloaded 
cHANPs and the results are compared also with NPs 
after PEGylation.
The relaxation time values of Gd-DTPA and 
cHANPs are first calculated at 37°C and 1.5 T (Mini-
spec mq60). For all magnetic resonance instruments, 
results clearly show that the relaxation time for Gd-
DTPA entrapped within cHANPs is shorter than that 
of the ‘free’ CA.
Also in these conditions, after PEGylation for both 
strategies, we have achieved a T
1
 of 1590 ms which 
corresponds to 20 μM of Gd-loaded cHANPs sus-
pension (measured through ICP-MS), while 100 μM 
of Gd-DTPA free in solution is required to achieve 
a comparable T
1
 (Figure 6). Indeed, the relaxation 
time reported for cHANPs is achieved with a con-
centration about five-times lower than that of the free 
 Gd-DTPA.
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Figure 4. HA-PEG-VS reaction in microfluidics. (A) Schematic illustration of the Michael addition reaction mechanism 
of thiolated HA with PEG-VS. (B) TEM and (C) FE-SEM images of the PEGylated cHANPs in water after 48 h. 
cHANP: Crosslinked hyaluronic acid nanoparticle; FE-SEM: Field emission scanning electron microscope; 
TEM: Transmission electron microscope.
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Discussion
Among different CAs for MRI, Gd chelates based 
ones, owing to its enhanced stability and paramagnetic 
properties, are used in up to 30% of clinical MRI scans 
and are considered clinically approved for human use. 
However, their effectiveness remains limited owing 
to nephrotoxicity effects, intracranial deposition [25], 
lack of tissue specificity, low relaxivity, short in vivo 
circulation time and poor specificity which restraints 
its application.
Research focusing on polymeric hybrid nanostruc-
tures for bioengineering, nanomedicine and theranos-
tic applications has undergone drastic transformations 
in the past few decades. The interest of these nanosys-
tems particularly relies on the new dimensions and new 
potentials they offered regarding their enhanced interac-
tions with micro- or macro-environments. In fact, they 
can penetrate living tissues, and encapsulate, protect and 
deliver the drug into specific targeted sites. Furthermore, 
systems with monodisperse size under 100 nm are likely 
to improve delivery functions to the tissues, stability of 
the metal chelates and provide enhanced relaxometric 
properties of the Gd-based CAs. In fact, it is also highly 
interesting to have a monodisperse size of the core mate-
rial, which is one of the most important parameters for 
a uniform biodistribution. Microfluidics has demon-
strated its ability to improve size- and composition- con-
trol in the field of NP synthesis [11,15].
In a recent work [40], we have explored the impact 
of crosslinked and uncrosslinked biopolymer matrices 
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Figure 5. Fourier transform infrared spectra analysis. Comparison of FT-IR spectra of (A) PEGylated cHANPs, (B) 
HA-SH and (C) PEG-VS precursors. 
cHANP: Crosslinked hyaluronic acid nanoparticle; FT-IR: Fourier transform infrared
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on relaxometric properties of CAs where the contribu-
tion to the enhancement of CAs is highlighted and 
attributed to the reduced mobility of water within the 
hydrogel. The idea was that the knowledge of these 
complex systems could be scaled to nanoscale dimen-
sions, inspiring the development of a new class of nano-
structured MRI CAs with highly tunable relaxometric 
properties. Moreover, the possibility to modulate the 
properties of the NPs through a flexible microfluidic 
platform to impact the relaxometric properties of the 
CAs without chemical modification of the chelates has 
been tested.
In the previous work [21], we have matched a nano-
precipitation phenomenon plus a crosslinking reaction 
in a microfluidic device for the production of cHANPs 
entrapping Gd-DTPA. By adding Gd to the main-
stream, a significant interference is observed that we 
have controlled to obtain improved properties of the 
MRI CAs.
However, due to the increasing relevance of the 
multimodal imaging, the possibility to have a nano-
structured system with improved relaxometric proper-
ties and simultaneous imaging modalities, controlled 
release and delivery behavior is required for a  successful 
diagnosis and therapy.
In this perspective, after the optimization of the Gd-
DTPA entrapment within the cHANPs as previously 
reported, we have performed a successful simultane-
ous encapsulation of free dyes with the aim to confirm 
the versatility of our designed microfluidic platform. 
ATTO 633 or ATTO 488, were simultaneously encap-
sulated together with Gd-DTPA providing the possi-
bility to perform not only a boosted MRI imaging but 
also a multimodal imaging and a therapeutic approach, 
eventually.
Furthermore, a batch PEGylation reaction has been 
conducted on the cHANPs put forward our struc-
tures for an in vivo long circulation half-life. Indeed, 
owing to its high binding affinity for CD44, which 
is abundant in the tumor tissue, HA has been exten-
sively investigated for the development of tumor tar-
geted imaging agents and drug delivery systems [41]. 
However, it is worthy of note that the targetability of 
HA is compromised by its binding to other receptors 
in normal organs, such as the LYVE-1 receptor on cells 
located in the lymphatics and the HARE receptor on 
liver sinusoidal endothelial cells [42]. Therefore, it can 
be expected that modulation of the binding affinity 
of HA to the receptors may affect in vivo biodistribu-
tion and, eventually, targetability by a combination 
of active and passive targeting mechanisms. After the 
optimization of the encapsulation, aiming to control 
delivery properties of cHANPs by PEGylation, dif-
ferent PEGylation reactions are performed for the 
cHANPs, confirming an enhancement of the MRI 
signal of about five-times, even after the PEGylation 
reaction. Preliminary studies about in vitro toxicity 
and MRI acquisition highlight the powerful effect of 
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Figure 6. In vitro relaxation time distribution. 
Relaxation time distribution reported for Gd-DTPA in 
water solution at 20 and 100 μM; PEGylated loaded 
cHANPs at standard conditions obtained using 4% v/v 
DVS in the side channels, at pH 12.3, reported at 20 μM 
of Gd-DTPA. 
cHANP: Crosslinked hyaluronic acid nanoparticle; 
DVS: Divinyl sulfone.
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the produced nanostructures for application in clinical 
imaging.
In addition, the platform is exploited to synthesize in 
a one-step manner biocompatible PEGylated cHANPs 
starting by HA and PEG-VS, entrapping Gd-DTPA 
and several types of fluorophores for application in 
diagnostics and therapy. The exceptional strength of 
the proposed work, compared with other investiga-
tions related to the formation of nanostructures, is the 
ability to generalize our approach to other biomaterials 
preserving the boosting of the relaxometric properties 
of the entrapped gadolinium-based CA [43]. Results 
show that our microfluidic approach can be applied to 
various other polymers maintaining unchanged pro-
cess parameters in terms of optimal flow rate ratio and 
range concentration to obtain easily several polysac-
charide NPs in a one-step manner, providing a careful 
control of the NP characteristics.
Conclusion
Several efforts have been recently reported about the 
possibility to increase the relaxivity of the CAs for 
MRI without the chemical modification of the che-
lates. Here, we investigated how hydrogel charac-
teristics tuned through a microfluidic flow focusing 
approach can impact on the relaxometric properties of 
MRI CAs.
Our microfluidic platform confirms its effectiveness 
in the production of stable NPs that can entrap one 
or more active compounds for multimodal imaging or 
theranostic applications. The stability achieved in the 
proposed microfluidic flow focusing approach enables 
the post processing PEGylation of the cHANPs 
avoiding the release of the cargo. Furthermore, an 
improvement of the proposed platform is reported 
by presenting in a one-step strategy the synthesis of 
the PEGylated cHANPs entrapping Gd-DTPA and a 
fluorophore through a controlled co-nanoprecipitation 
in the microfluidic flow focusing system. PEGylated 
cHANPs performances have been assessed in terms 
of longitudinal relaxation rates: a relaxation rate T
1
 
of 1590 ms is achieved with 24 μM of Gd-loaded 
cHANPs while 100 μM of Gd-DTPA solution is 
required to reach similar T
1
 (about 1724 ms). Results 
confirm the concept that the entrapment of the Gd-
based CAs within the hydrogel structure can enhance 
relaxivity even after PEGylation reaction, thus enable 
potentially low administration dosage overcoming 
potentially several side effects related to the CAs. The 
proposed microfluidic platform could be applied to 
study the mechanisms involved in several combina-
tions of different types of polymers and metal ions. It 
is important to underline that our platform is easy to 
move not only to the encapsulation of several drugs 
for a multimodal imaging or also for application in 
diagnostics and therapy, simultaneously. Our findings 
could contribute significantly to the prompt introduc-
tion of new advances in the synthesis of medical prod-
ucts through a high versatile microfluidic platform. In 
these perspectives, future outlooks are addressed to the 
ability to build a library of functional nanostructures 
on the needs of a pathology, field and material proper-
ties. Next steps are also addressed to in vivo study for 
a specific pathology and to perform an active targeting 
of cHANPs to reach a specific tissue.
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Summary points
•	 Highly versatile microfluidic platform to design nanostructures for application in diagnosis and therapy.
•	 Controlled nanoprecipitation in a microfluidic flow focusing system.
•	 Modulated crosslinking reaction in microfluidics.
•	 Simultaneous encapsulation of different active agents within nanoparticles.
•	 Fine-tuning of the nanoparticle’ characteristics.
•	 Nanoprecipitation, crosslinking, encapsulation and PEGylation reaction in a one-step microfluidic process.
•	 Boosting of the relaxometric properties of Gd-DTPA entrapped within cHANPs and PEGylated cHANPs 
compared with the free contrast agent.
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